Silence Therapeutics plc

Board/Management Information • Nov 18, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2140T

Silence Therapeutics PLC

18 November 2013

Silence Therapeutics plc

Notice of Investor Event and appointment of Nominated Adviser and Broker

18 November 2013

As announced on 23 October 2013, Silence Therapeutics plc ("Silence" or the "Company") is hosting an Investor event for investors and analysts in London on Monday 18 November 2013. The purpose of the event is to explain the background to Silence's technology and outline its potential. The presentation will be available from the Company's website (silence-therapeutics.com/investor-relations) from 5pm on 18 November 2013.

In the presentation the Company will outline its plans for further drug trials, including the head and neck cancer trial announced separately today, and for targeting Angiopoietin 2 (Ang-2), a well studied vascular inflammatory agent, in the lung and systemically.  The Company will also present its updated and strengthened board, senior management and scientific advisory board also announced separately today.  No further material new financial or other information will be presented.

Additionally, the Company announces the appointment of Canaccord Genuity Limited as the Company's nominated adviser and broker with immediate effect.

For further information please contact:

Silence Therapeutics plc Ali Mortazavi, Chief Executive	+44 (0)333 988 0140 [email protected]
Timothy Freeborn, Finance Director	[email protected]
Annie Cheng, Chief Operating Officer	[email protected]
Canaccord Genuity Limited	+44 (0)20 7523 8350
Lucy Tilley Dr Julian Feneley Henry Fitzgerald-O'Connor

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPEAKFSFSXDFFF